• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

恶唑烷酮类药物RWJ-416457对耐利奈唑胺和对利奈唑胺敏感的葡萄球菌及肠球菌的体外活性

In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.

作者信息

Livermore David M, Warner Marina, Mushtaq Shazad, North Sarah, Woodford Neil

机构信息

Antibiotic Resistance Monitoring and Reference Laboratory, Health Protection Agency Centre for Infections, 61 Colindale Avenue, London NW9 5EQ, United Kingdom.

出版信息

Antimicrob Agents Chemother. 2007 Mar;51(3):1112-4. doi: 10.1128/AAC.01347-06. Epub 2007 Jan 8.

DOI:10.1128/AAC.01347-06
PMID:17210773
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1803128/
Abstract

RWJ-416457, a novel oxazolidinone, had modal MICs of 0.5 to 1 microg/ml for linezolid-susceptible staphylococci and enterococci, versus linezolid MICs for these organisms of 1 or 2 microg/ml. RWJ-416457 MICs for mutants with 23S rRNA mutations were 2 to 32 microg/ml, versus linezolid MICs of 8 to 64 microg/ml; actual values reflected the proportion of gene copies mutated.

摘要

新型恶唑烷酮类药物RWJ - 416457对利奈唑胺敏感的葡萄球菌和肠球菌的最低抑菌浓度（MIC）范围为0.5至1微克/毫升，而这些菌株对利奈唑胺的MIC为1或2微克/毫升。对于具有23S rRNA突变的突变体，RWJ - 416457的MIC为2至32微克/毫升，而利奈唑胺的MIC为8至64微克/毫升；实际数值反映了发生突变的基因拷贝比例。

相似文献

1
In vitro activity of the oxazolidinone RWJ-416457 against linezolid-resistant and -susceptible staphylococci and enterococci.恶唑烷酮类药物RWJ-416457对耐利奈唑胺和对利奈唑胺敏感的葡萄球菌及肠球菌的体外活性
Antimicrob Agents Chemother. 2007 Mar;51(3):1112-4. doi: 10.1128/AAC.01347-06. Epub 2007 Jan 8.
2
Characterisation of Staphylococcus aureus and Enterococcus faecalis mutants with reduced susceptibility to the investigational oxazolidinone RWJ-416457.研究型恶唑烷酮类药物 RWJ-416457 低敏性金黄色葡萄球菌和粪肠球菌突变株的特性研究。
Int J Antimicrob Agents. 2010 Nov;36(5):424-9. doi: 10.1016/j.ijantimicag.2010.07.007. Epub 2010 Sep 17.
3
A comparative in-vitro evaluation of resistance selection after exposure to teicoplanin, vancomycin, linezolid and quinupristin-dalfopristin in Staphylococcus aureus and Enterococcus spp.金黄色葡萄球菌和肠球菌属暴露于替考拉宁、万古霉素、利奈唑胺和奎奴普丁-达福普汀后耐药性选择的体外比较评估
Clin Microbiol Infect. 2008 Jun;14(6):608-11. doi: 10.1111/j.1469-0691.2008.01993.x. Epub 2008 Apr 5.
4
Linezolid-resistant clinical isolates of enterococci and Staphylococcus cohnii from a multicentre study in China: molecular epidemiology and resistance mechanisms.中国多中心研究中耐利奈唑胺的肠球菌和科氏葡萄球菌临床分离株：分子流行病学和耐药机制。
Int J Antimicrob Agents. 2013 Oct;42(4):317-21. doi: 10.1016/j.ijantimicag.2013.06.008. Epub 2013 Jul 20.
5
Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.恶唑烷酮TR-700对利奈唑胺敏感及耐药葡萄球菌和肠球菌的活性。
J Antimicrob Chemother. 2009 Apr;63(4):713-5. doi: 10.1093/jac/dkp002. Epub 2009 Jan 22.
6
In vitro activities of Daptomycin, Linezolid, and Quinupristin-Dalfopristin against a challenge panel of Staphylococci and Enterococci, including vancomycin-intermediate staphylococcus aureus and vancomycin-resistant Enterococcus faecium.达托霉素、利奈唑胺和奎奴普丁-达福普汀对包括万古霉素中介金黄色葡萄球菌和万古霉素耐药粪肠球菌在内的葡萄球菌和肠球菌挑战组的体外活性。
Microb Drug Resist. 2003 Winter;9(4):389-93. doi: 10.1089/107662903322762833.
7
Intensive care unit dissemination of multiple clones of linezolid-resistant Enterococcus faecalis and Enterococcus faecium.重症监护病房中耐(linezolid)利奈唑烷(Enterococcus faecalis)肠球菌和屎肠球菌的多个克隆株的传播。
J Antimicrob Chemother. 2012 Aug;67(8):1819-23. doi: 10.1093/jac/dks146. Epub 2012 Apr 24.
8
Comparative in vitro activities and postantibiotic effects of the oxazolidinone compounds eperezolid (PNU-100592) and linezolid (PNU-100766) versus vancomycin against Staphylococcus aureus, coagulase-negative staphylococci, Enterococcus faecalis, and Enterococcus faecium.恶唑烷酮类化合物依哌唑胺（PNU - 100592）和利奈唑胺（PNU - 100766）与万古霉素相比，对金黄色葡萄球菌、凝固酶阴性葡萄球菌、粪肠球菌和屎肠球菌的体外比较活性及抗生素后效应。
Antimicrob Agents Chemother. 1998 Mar;42(3):721-4. doi: 10.1128/AAC.42.3.721.
9
Comparative activity of linezolid against staphylococci and enterococci isolated in Italy.利奈唑胺对意大利分离的葡萄球菌和肠球菌的比较活性。
Clin Microbiol Infect. 2002 Jun;8(6):368-72. doi: 10.1046/j.1469-0691.2002.00429.x.
10
A novel gene, optrA, that confers transferable resistance to oxazolidinones and phenicols and its presence in Enterococcus faecalis and Enterococcus faecium of human and animal origin.一种赋予对恶唑烷酮类和酚类药物可转移抗性的新基因optrA，以及它在人和动物源粪肠球菌和屎肠球菌中的存在情况。
J Antimicrob Chemother. 2015 Aug;70(8):2182-90. doi: 10.1093/jac/dkv116. Epub 2015 May 14.

引用本文的文献

1
Diversity in Adaptive Evolution of Methicillin-Resistant Clinical Isolates Under Exposure to Continuous Linezolid Stress in vitro.耐甲氧西林临床分离株在体外持续暴露于利奈唑胺压力下适应性进化的多样性
Infect Drug Resist. 2025 Feb 11;18:819-834. doi: 10.2147/IDR.S493139. eCollection 2025.
2
Resistance to linezolid in Staphylococcus aureus by mutation, modification, and acquisition of genes.金黄色葡萄球菌通过基因突变、修饰和基因获得对利奈唑胺产生耐药性。
J Antibiot (Tokyo). 2025 Jan;78(1):4-13. doi: 10.1038/s41429-024-00778-4. Epub 2024 Oct 17.
3
Genomic Insights Into Last-Line Antimicrobial Resistance in Multidrug-Resistant and Vancomycin-Resistant .多重耐药和耐万古霉素菌最后一线抗菌药物耐药性的基因组学见解
Front Microbiol. 2021 Mar 16;12:637656. doi: 10.3389/fmicb.2021.637656. eCollection 2021.
4
Linezolid Resistance in Staphylococci.葡萄球菌对利奈唑胺的耐药性
Pharmaceuticals (Basel). 2010 Jun 24;3(7):1988-2006. doi: 10.3390/ph3071988.
5
Structural insights into species-specific features of the ribosome from the pathogen Staphylococcus aureus.对病原菌金黄色葡萄球菌核糖体物种特异性特征的结构洞察。
Proc Natl Acad Sci U S A. 2015 Oct 27;112(43):E5805-14. doi: 10.1073/pnas.1517952112. Epub 2015 Oct 13.
6
Mechanisms of linezolid resistance in staphylococci and enterococci isolated from two teaching hospitals in Shanghai, China.中国上海两家教学医院分离出的葡萄球菌和肠球菌中利奈唑胺耐药机制研究
BMC Microbiol. 2014 Nov 25;14:292. doi: 10.1186/s12866-014-0292-5.
7
Transferable plasmid-mediated resistance to linezolid due to cfr in a human clinical isolate of Enterococcus faecalis.可转移质粒介导的利奈唑胺耐药性由于 cfr 在粪肠球菌的人类临床分离株中。
Antimicrob Agents Chemother. 2012 Jul;56(7):3917-22. doi: 10.1128/AAC.00419-12. Epub 2012 Apr 9.
8
Resistance to linezolid caused by modifications at its binding site on the ribosome.核糖体结合部位修饰导致对利奈唑胺的耐药性。
Antimicrob Agents Chemother. 2012 Feb;56(2):603-12. doi: 10.1128/AAC.05702-11. Epub 2011 Dec 5.
9
Current and novel antibiotics against resistant Gram-positive bacteria.当前和新型抗生素治疗耐药革兰阳性菌感染。
Infect Drug Resist. 2008;1:27-44. doi: 10.2147/idr.s3545. Epub 2008 Sep 9.
10
Mutations in 23S rRNA at the peptidyl transferase center and their relationship to linezolid binding and cross-resistance.在肽转移酶中心的 23S rRNA 突变及其与利奈唑胺结合和交叉耐药的关系。
Antimicrob Agents Chemother. 2010 Nov;54(11):4705-13. doi: 10.1128/AAC.00644-10. Epub 2010 Aug 9.

本文引用的文献

1
In vitro antibacterial activity of the pyrrolopyrazolyl-substituted oxazolidinone RWJ-416457.吡咯并吡唑基取代恶唑烷酮RWJ-416457的体外抗菌活性
Antimicrob Agents Chemother. 2007 Jan;51(1):361-5. doi: 10.1128/AAC.01017-06. Epub 2006 Nov 13.
2
Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections.利奈唑胺与万古霉素治疗复杂性皮肤及软组织感染的比较
Antimicrob Agents Chemother. 2005 Jun;49(6):2260-6. doi: 10.1128/AAC.49.6.2260-2266.2005.
3
Antimicrobial resistance to linezolid.对利奈唑胺的抗菌药物耐药性。
Clin Infect Dis. 2004 Oct 1;39(7):1010-5. doi: 10.1086/423841. Epub 2004 Sep 10.
4
Antimicrobial susceptibility of the pathogens of bacteraemia in the UK and Ireland 2001-2002: the BSAC Bacteraemia Resistance Surveillance Programme.2001 - 2002年英国和爱尔兰血流感染病原体的抗菌药物敏感性：英国抗菌化疗学会血流感染耐药性监测项目
J Antimicrob Chemother. 2004 Jun;53(6):1018-32. doi: 10.1093/jac/dkh232. Epub 2004 May 5.
5
Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia.利奈唑胺与万古霉素对比：耐甲氧西林金黄色葡萄球菌医院获得性肺炎患者两项双盲研究的分析
Chest. 2003 Nov;124(5):1789-97.
6
Rapid detection and estimation by pyrosequencing of 23S rRNA genes with a single nucleotide polymorphism conferring linezolid resistance in Enterococci.通过焦磷酸测序对粪肠球菌中具有导致利奈唑胺耐药性的单核苷酸多态性的23S rRNA基因进行快速检测和评估。
Antimicrob Agents Chemother. 2003 Nov;47(11):3620-2. doi: 10.1128/AAC.47.11.3620-3622.2003.
7
Efficacy of linezolid versus comparator therapies in Gram-positive infections.利奈唑胺与对照疗法治疗革兰氏阳性菌感染的疗效比较
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii27-35. doi: 10.1093/jac/dkg251.
8
Linezolid in vitro: mechanism and antibacterial spectrum.利奈唑胺的体外作用机制及抗菌谱
J Antimicrob Chemother. 2003 May;51 Suppl 2:ii9-16. doi: 10.1093/jac/dkg249.
9
Insertional inactivation of mutS in Staphylococcus aureus reveals potential for elevated mutation frequencies, although the prevalence of mutators in clinical isolates is low.金黄色葡萄球菌中mutS的插入失活揭示了突变频率升高的可能性，尽管临床分离株中突变体的流行率较低。
J Antimicrob Chemother. 2002 Aug;50(2):161-9. doi: 10.1093/jac/dkf118.
10
Dominance of EMRSA-15 and -16 among MRSA causing nosocomial bacteraemia in the UK: analysis of isolates from the European Antimicrobial Resistance Surveillance System (EARSS).英国耐甲氧西林金黄色葡萄球菌（MRSA）引起医院获得性菌血症时EMRSA - 15和 - 16的优势地位：对欧洲抗菌药物耐药性监测系统（EARSS）分离株的分析
J Antimicrob Chemother. 2001 Jul;48(1):143-4. doi: 10.1093/jac/48.1.143.